Jeffery Davis
Psychiatric/Mental Health · Creve Coeur, MONPI 1639402738
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 47.7% of the total. Reporting peaked in 2024 at $12,391 and has fallen 75.2% since, to $3,075 in 2025. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 330 payments — averaging $71.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$11K
- UCB, Inc.$6K
- Neurocrine Biosciences, Inc.$2K
- Alkermes, Inc.$994
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$554
- Johnson & Johnson$545
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$14,03059%
- Travel & lodging$1,6767%
- Food & beverage$7,70933%
- Education$1991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 98 | $11,257 |
| UCB, Inc. | 21 | $6,169 |
| Neurocrine Biosciences, Inc. | 50 | $1,918 |
| Alkermes, Inc. | 33 | $994 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $554 |
| Johnson & Johnson | 23 | $545 |
| Acadia Pharmaceuticals Inc | 18 | $504 |
| Otsuka America Pharmaceutical, Inc. | 10 | $304 |
| Alpha Cognition USA, Inc. | 2 | $246 |
| Avanir Pharmaceuticals, Inc. | 6 | $199 |
| E.r. Squibb & Sons, L.L.C. | 5 | $192 |
| Indivior Inc. | 9 | $155 |
| Vanda Pharmaceuticals Inc. | 6 | $122 |
| Biogen | 5 | $100 |
| Organogenesis Inc. | 1 | $82 |
| Lundbeck LLC | 3 | $66 |
| Sunovion Pharmaceuticals Inc. | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Noven Therapeutics, LLC | 2 | $30 |
| AbbVie | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,615 in reported general payments places this provider in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 36 | $184,541 |
| IngrezzaValbenazine Tosylate | 24 | $178,532 |
| RexultiBrexpiprazole | 83 | $72,509 |
| Austedo XrDeutetrabenazine | 11 | $65,091 |
| Invega SustennaPaliperidone Palmitate | 14 | $41,771 |
| NuplazidPimavanserin Tartrate | 11 | $27,957 |
| BriviactBrivaracetam | 12 | $8,829 |
| NamzaricMemantine Hcl/Donepezil Hcl | 23 | $6,657 |
| Divalproex Sodium | 123 | $4,433 |
| BelsomraSuvorexant | 24 | $4,132 |
| Mirtazapine | 255 | $3,462 |
| Duloxetine Hcl | 177 | $2,724 |
| Sertraline Hcl | 320 | $2,076 |
| Memantine Hcl | 54 | $1,417 |
| Buspirone Hcl | 136 | $1,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $11,257 | $249,63247 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,918 | $178,53224 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $304 | $72,50983 claims |
| Johnson & JohnsonInvega Sustenna | $545 | $41,77114 claims |
| Acadia Pharmaceuticals IncNuplazid | $504 | $27,95711 claims |
| UCB, Inc.Briviact | $6,169 | $8,82912 claims |
| AbbVieNamzaric | $29 | $6,65723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Creve Coeur
- Elizabeth BerryCreve Coeur$9K
- Michelle GarrettCreve Coeur$6K
- Miles HartmanCreve Coeur$6K
- Aldijana SacicSaint Louis$510K
- Erin DuvallSpringfield$275K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
- Emily WoukSpringfield$90K
- Kristerpher BrimberryPoplar Bluff$74K
- Matthew LindquistSt Louis$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.